Caricamento...
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics
BACKGROUND: Although hydrochlorothiazide (HCTZ) is a well‐established first‐line antihypertensive in the United States, <50% of HCTZ treated patients achieve blood pressure (BP) control. Thus, identifying biomarkers that could predict the BP response to HCTZ is critically important. In this study...
Salvato in:
| Pubblicato in: | J Am Heart Assoc |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5778957/ https://ncbi.nlm.nih.gov/pubmed/29288159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.006656 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|